- Tristel, a manufacturer of infection prevention and contamination control products, grew its turnover by 19% to £20.3 million in the year ended 30 June, ahead of expectations.

Overseas sales rose by 43% to £9.6 million, representing 47% of total sales compared with 39% the year before.

Pre-tax profit before share-based payments increased by 24% to £4.1 million.

The company has lifted its full year dividend by 21% to 4.03p.

Paul Swinney, chief executive of Tristel, said: "We are pleased with the progress made this year. Sales and profitability exceeded both market expectations and our internal plan. The drivers were growth in our overseas operations, favourable exchange rates and the acquisition of our Australian distributor's business.

"The North American regulatory programme is progressing well, with our first submission made to the EPA. We were disappointed to learn in early October that there will be delay to the approval timetable, but this does not change our expectation of first sales in North America in financial year 2018-19.

"Our investment in MobileODT involves us for the first time in an emerging healthcare market - point-of-care diagnostic devices connected to smart phones that require high-level disinfection. We believe this represents a significant future opportunity for Tristel."

At 8:18am: [LON:TSTL] Tristel PLC share price was -7.5p at 287.5p

Story provided by